|
On The Fly
|
Check out this evening's… ShowHide Related Items >><< - 01/21/21
- Sierra Wireless CEO Thexton to retire
- 11/18/20
- Sierra Wireless completes divestiture of automotive embedded module product line
- 07/23/20
- Sierra Wireless to divest automotive embedded product line for $165M
- 01/21/21
- Seagate says 2020 'a very challenging year'
- 01/19/21
- Nidec files patent infringement suit against Seagate
- 12/28/20
- Seagate appoints Prat Bhatt to Board of Directors
- 12/16/20
- Intel announces next generation of memory and storage products
- 01/05/21
- HoldCo expresses concerns regarding Boston Private Financial, SVB Financial deal
- 01/04/21
- SVB Financial to acquire Boston Private Financial in $900M cash and stock deal
- 12/08/20
- Clearbanc, Silicon Valley Bank partner on new capital program
- 11/30/20
- SVB Financial to acquire WestRiver Group's debt investment business
- $143.94 /
-0.635 (-0.44%) - 01/21/21
- PPG says demand continues to improve in many of its end-use markets
- 01/11/21
- PPG appoints Bhaskar Ramachandran as CIO
- 01/11/21
- PPG reaches definitive agreement to acquire Worwag
- 01/08/21
- PPG to acquire VersaFlex Family of Companies
- 01/05/21
- Precigen announces FDA clearance of IND application for PRGN-2012
- 12/07/20
- Precigen: PRGN-3006 safe, well-tolerated to date
- 11/16/20
- Precigen announces dosing of first patients in ongoing PRGN-3005, -3006 trials
- 10/15/20
- Precigen's UltraPorator system receives FDA clearance
- 01/04/21
- Bank OZK increases quarterly cash dividend to 27.75c per share
- 10/08/20
- Bank OZK reports resignation of Chief Credit Officer of the bank
- 10/01/20
- Bank OZK raises quarterly dividend to 27.5c per share
- 01/21/21
- MediciNova rises 14% after disclosing activist stake by 3D Investment Partners
- 12/29/20
- MediciNova receives notice of allowance for patent covering MN-166
- 12/15/20
- MediciNova to be added to Nasdaq Biotechnology Index at open on 12/21
- 11/25/20
- MediciNova's MN-166 shows retinal thinning attenuation in Phase 2b trial
- 01/21/21
- Intuitive Surgical says overall procedure growth was 6% in Q4
- 10/27/20
- Intuitive Surgical launches $100M venture capital fund
- 10/15/20
- Intuitive Surgical slides 2.8% to $720 per share after Q3 results
- 10/15/20
- Intuitive Surgical's first 9 months of 2020 saw 'significant impact' from COVID
- 01/21/21
- IBM down 6.5% at $123.24 after Q4 earnings, conference call outlook
- 01/21/21
- IBM sees FY21 'revenue growth based on current spot rates'
- 01/21/21
- IBM NewCo CEO Martin Schroeter says company has 'tremendous potential'
- 01/21/21
- IBM CFO says optimizing NewCo to have a 'leaner' operating model
- 01/21/21
- Fluidigm gets CE-IVD mark for its saliva-based Advanta assay for Covid
- 01/05/21
- Fluidigm announces publication on potential for Imaging Mass Cytometry
- 11/24/20
- Fluidigm says India CDSCO grants commercial license for Advanta Dx Assay
- 11/19/20
- Fluidigm announces results of study using Imaging Mass Cytometry
- 01/21/21
- Ford sees 2020 underfunded status for pension of about $6.7B
- 01/21/21
- Ford to replace Takata airbag inflators in certain models at cost of $610M
- 01/19/21
- EU passenger car registrations down 3.3% in December
- 01/11/21
- Ford to stop manufacturing in Brazil, sees pre-tax special item charges of $4.1B
- $91.61 /
-1.6101 (-1.73%) - 01/20/21
- North American rail traffic rose 8.6% in the week ended January 16
- 01/14/21
- North American rail traffic rose 3% in the week ended January 9
- 01/07/21
- North American rail traffic rose 1.3% in the week ended January 2
- 12/31/20
- North American rail traffic rose 7% in week ended December 26
- 01/21/21
- Amarin announces CSC included icosapent ethyl in CD prevention guidelines
- 01/07/21
- Amarin provides outlook on 2021 cash & expenses
- 12/14/20
- Amarin says Vascepa reduced Covid inflammation by 25% in early study
- 12/14/20
- Amarin announces presentation of Vascepa findings at conference
- 01/21/21
- Aldeyra rises 6% after 1.37M share purchase disclosed by Perceptive Advisors
- 01/07/21
- Aldeyra announces top-line results from run-in cohort in Tranquility study
- 12/22/20
- Aldeyra confirms SARS-CoV-2 antiviral activity of ADX-1612
- 12/17/20
- Aldeyra initiates Phase 2 trials of ADX-629
- 01/14/21
- Aurora Cannabis announces Canadian retail sales deal with Great North
- 01/06/21
- Aurora Cannabis rises 13.7%
- 01/06/21
- Aurora Cannabis rises 13.8%
- 12/16/20
- Aurora Cannabis provides business update, closing Aurora Sun facility
- 01/08/21 Oppenheimer
- Oppenheimer calls SVB Financial acquisition of Boston Private a 'good move'
- 01/05/21 DA Davidson
- SVB Financial price target raised to $400 from $365 at DA Davidson
- 01/05/21 Raymond James
- SVB Financial price target raised to $440 from $325 at Raymond James
- 01/05/21 RBC Capital
- SVB Financial price target raised to $437 from $320 at RBC Capital
- 01/08/21 UBS
- Western Alliance upgraded to Buy from Neutral at UBS
- 01/04/21 Stephens
- Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
- 12/15/20 Truist
- Truist raises price targets on select regional banks
- 11/04/20 Stephens
- Western Alliance resumed with an Overweight at Stephens
- 12/17/20 Seaport Global
- Seaport Global rolls out coverage of Regional and Community Banks with 4 Buys
- 12/17/20 Seaport Global
- Independent Bank initiated with a Neutral at Seaport Global
- 10/26/20 Compass Point
- Independent Bank upgraded to Buy from Neutral at Compass Point
- 06/24/20 Piper Sandler
- Independent Bank downgraded to Neutral from Overweight at Piper Sandler
- 06/17/20 Raymond James
- Bank OZK upgraded to Outperform from Market Perform at Raymond James
- 06/17/20 Citi
- Bank OZK downgraded to Neutral from Buy at Citi
- 06/17/20 Raymond James
- Bank OZK upgraded to Outperform from Market Perform at Raymond James
- 04/28/20 Truist
- Bank OZK price target raised to $22 from $19 at SunTrust
- 12/17/20 BTIG
- Illumina upgraded to Buy from Neutral at BTIG
- 11/09/20 Piper Sandler
- Buy companies with COVID-19 tests on today's selloff, says Piper Sandler
- 10/19/20 Piper Sandler
- Fluidigm test pact in Texas 'another validation,' says Piper Sandler
- 09/29/20 Piper Sandler
- Piper Sandler would be buyers of Fluidigm given recent pullback
- 01/14/21
- Fly Intel: Top five analyst initiations
- 01/14/21 B. Riley Securities
- Sierra Wireless initiated with a Buy at B. Riley Securities
- 11/25/20 Colliers
- Sierra Wireless initiated with a Buy at Colliers
- 02/14/20 Roth Capital
- Roth Capital sees upside in Sierra Wireless after 2020 transition year
- 01/08/21 Jefferies
- Aldeyra could double if topline of TRANQUILITY study positive, says Jefferies
- 01/08/21 Citi
- Aldeyra shares have 'plenty of upside' despite 26% rally, says Citi
- 01/07/21 Alliance Global Partners
- Aldeyra in an 'enviable position' after Phase 3 Tranquility data, says AGP
- 12/16/20 Berenberg
- Berenberg starts Aldeyra with Buy, sees near-term catalysts
- 01/08/21 Piper Sandler
- Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
- 12/28/20 Cantor Fitzgerald
- Vascepa showing positive year-over-year trends, says Cantor Fitzgerald
- 12/23/20 Goldman Sachs
- Amarin price target lowered to $6 from $8 at Goldman Sachs
- 12/14/20 Piper Sandler
- Amarin's Vascepa showed 'encouraging results' in Covid patients, says Piper
- 10/20/20 Morgan Stanley
- Morgan Stanley continues to view IBM as 'a 2022 stock'
- 10/20/20 Citi
- IBM is 'getting even more complex,' says Citi
- 10/20/20 BMO Capital
- IBM price target lowered to $138 from $140 at BMO Capital
- 10/09/20 Morgan Stanley
- IBM price target raised to $140 from $128 at Morgan Stanley
- 01/21/21 Barclays
- Seagate price target raised to $60 from $41 at Barclays
- 01/20/21 Wedbush
- Seagate price target raised to $56 from $47 at Wedbush
- 01/19/21 Northland
- Seagate price target raised to $72 from $65 at Northland
- 01/19/21 Loop Capital
- Seagate price target raised to $70 from $60 at Loop Capital
- $143.94 /
-0.635 (-0.44%) - 01/20/21 Citi
- Citi adds PPG to US Focus List, removes FMC
- 01/14/21 Berenberg
- PPG upgraded to Buy with $165 price target at Berenberg
- 01/14/21 Berenberg
- PPG upgraded to Buy from Hold at Berenberg
- 12/01/20 Deutsche Bank
- PPG price target raised to $165 from $155 at Deutsche Bank
- 12/15/20 Morgan Stanley
- Intuitive Surgical downgraded to Equal Weight on valuation at Morgan Stanley
- 12/15/20 Morgan Stanley
- Intuitive Surgical downgraded to Equal Weight from Overweight at Morgan Stanley
- 11/24/20 Raymond James
- Intuitive Surgical not surprised by J&J robot features, says Raymond James
- 10/16/20 JPMorgan
- Intuitive Surgical price target raised to $785 from $765 at JPMorgan
- $91.61 /
-1.6101 (-1.73%) - 01/20/21 Susquehanna
- Railroad recovery expected to continue in 2021, says Susquehanna
- 01/11/21 Citi
- CSX price target raised to $105 from $87 at Citi
- 12/10/20 Morgan Stanley
- Morgan Stanley downgrades CSX to Underweight with bar raised too high
- 12/10/20 Morgan Stanley
- CSX downgraded to Underweight from Equal Weight at Morgan Stanley
- 12/16/20 H.C. Wainwright
- Precigen price target raised to $10 from $8 at H.C. Wainwright
- 05/08/20
- Fly Intel: Top analyst initiations
- 05/08/20 H.C. Wainwright
- Precigen initiated with a Buy at H.C. Wainwright
- 01/06/21 BMO Capital
- Federal cannabis reform in U.S. likely to take time, says BMO Capital
- 12/17/20 BMO Capital
- Aurora Cannabis downgraded to Underperform from Market Perform at BMO Capital
- 12/04/20 Alliance Global Partners
- Alliance Global sees low odds of MORE Act passing this congressional session
- 12/02/20 Alliance Global Partners
- Alliance Global Partners sees UN cannabis reclassification helping legalization
- 01/20/21 Deutsche Bank
- Ford price target raised to $11 from $9 at Deutsche Bank
- 01/20/21 Deutsche Bank
- Ford named 'Catalyst Call: Buy Idea' at Deutsche Bank
- 01/05/21 Benchmark
- GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
- 12/23/20 Morgan Stanley
- Apple's potential EV entry represents 'new Tesla bear case,' says Morgan Stanley
- 01/21/21
- Western Alliance reports Q4 EPS $1.93 , consensus $1.32
- 10/22/20
- Western Alliance reports Q3 EPS $1.36, consensus $1.04
- 01/21/21
- Sierra Wireless sees Q4 revenue above street consensus of $116.5M
- 11/12/20
- Sierra Wireless cannot estimate COVID-19 impact on Q4 and beyond
- 11/12/20
- Sierra Wireless reports Q3 EPS (19c), consensus (15c)
- 08/06/20
- Sierra Wireless reports Q2 non-GAAP EPS (30c), consensus (35c)
- 01/21/21
- Seagate sees Q3 adjusted EPS $1.30, plus/minus 15c, consensus $1.26
- 01/21/21
- Seagate reports Q2 adjusted EPS $1.29, consensus $1.13
- 10/22/20
- Seagate sees Q2 adjusted EPS $1.10, plus/minus 15c, consensus $1.08
- 10/22/20
- Seagate reports Q1 adjusted EPS 93c, consensus 88c
- 01/21/21
- SVB Financial reports Q4 EPS $7.40, consensus $3.83
- 10/23/20
- SVB Financial reports Q3 EPS $8.47, consensus $5.14
- 07/23/20
- SVB Financial reports Q2 EPS $4.42, consensus $3.11
- $143.94 /
-0.635 (-0.44%) - 01/21/21
- PPG reports Q4 EPS $1.59, consensus $1.58
- 10/19/20
- PPG sees Q4 adjusted EPS $1.50-$1.57, consensus $1.44
- 10/19/20
- PPG reports Q3 adjusted EPS $1.93, consensus $1.92
- 11/09/20
- Precigen reports Q3 EPS (18c), consensus (14c)
- 08/10/20
- Precigen reports Q2 EPS (26c), consensus (13c)
- 01/21/21
- Bank OZK reports Q4 EPS 93c, consensus 78c
- 10/22/20
- Bank OZK reports Q3 EPS 84c, consensus 58c
- 07/23/20
- Bank OZK reports Q2 EPS 39c, consensus 33c
- 01/21/21
- Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12
- 01/13/21
- Intuitive Surgical sees 2020 revenue $4.36B, consensus $4.27B
- 01/13/21
- Intuitive Surgical sees Q4 revenue $1.33B, consensus $1.23B
- 01/21/21
- Independent Bank reports Q4 EPS $1.05, consensus $1.03
- 10/22/20
- Independent Bank reports Q3 adjusted EPS $1.07, consensus 81c
- 07/23/20
- Independent Bank Corp. reports Q2 EPS 76c, consensus 62c
- 01/21/21
- IBM reports Q4 Cloud & Cognitive Software revenue $6.8B, down 4.5%
- 01/21/21
- IBM reports Q4 adjusted EPS $2.07, consensus $1.79
- 01/21/21
- Notable companies reporting after market close
- 10/19/20
- IBM reports Q3 Cloud & Cognitive Software revenue $5.6B, up 7%
- 11/05/20
- Fluidigm reports Q3 EPS 3c, consensus (20c)
- 08/06/20
- Fluidigm reports Q2 EPS (18c), consensus (23c)
- 10/28/20
- Ford sees temporarily lower F-150 wholesale shipments in Q4
- 10/28/20
- Ford reports Q3 adjusted EBIT $3.6B
- 10/28/20
- Ford reports Q3 adjusted EPS 65c, consensus 16c
- 10/28/20
- Notable companies reporting after market close
- $91.61 /
-1.6101 (-1.73%) - 01/21/21
- CSX reports Q4 EPS 99c, consensus $1.00
- 10/21/20
- CSX reports Q3 EPS 96c, consensus 92c
- 10/21/20
- Notable companies reporting after market close
- 01/07/21
- Amarin sees FY20 revenue up 42% to $610M, consensus $619.19M
- 11/05/20
- Amarin reports Q3 non-GAAP EPS (1c), consensus 1c
- 08/04/20
- Amarin reports Q2 adjusted EPS 4c, consensus (7c)
- 11/05/20
- Aldeyra reports Q3 EPS (23c), consensus (27c)
- 08/06/20
- Aldeyra reports Q2 EPS (25c), consensus (34c)
- 11/09/20
- Aurora Cannabis reports Q1 revenue C$67.8M vs. C$67.5M in Q4
- 10/30/20
- Aurora Cannabis sees Q1 revenue at high end of $60M-$64M previous guidance
- 09/22/20
- Aurora Cannabis sees Q1 revenue $60M-$64M vs. $67.5M in Q4
- 09/22/20
- Aurora Cannabis reports Q4 revenue $72.1M, a 5% decline from last quarter
|
|
Hot Stocks
|
ViiV Healthcare, the… ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer (PFE) and Shionogi Limited as shareholders, announced that the U.S. FDA approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines, ViiV Healthcare's cabotegravir and Janssen's (JNJ) rilpivirine, dosed once monthly, as an option to replace the current antiretroviral regimen in those who are virologically suppressed on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy. ShowHide Related Items >><< - 01/21/21
- Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board
- 01/20/21
- Pfizer, BioNTech: COVID-19 vaccine elicits antibodies neutralizing pseudovirus
- 01/14/21
- Pfizer says FDA approves supplemental NDA for Xalkori
- 01/14/21
- Oragenics issues letter to stockholders on Terra CoV-2
- 01/21/21
- Addex Therapeutics receives IND approval to start study in epilepsy
- 01/19/21
- Royalty Pharma acquires royalty interest in Seltorexant from Minerva
- 01/19/21
- Minerva, Royalty Pharma announce sale of seltorexant royalty for up to $155M
- 01/15/21
- Halozyme says Janssen receives FDA approval of Darzalex Faspro
- 01/21/21
- BiondVax names Amir Reichman as new CEO
- 01/12/21
- Vir Biotechnology, GlaxoSmithKline to evaluate VIR-7832 in COVID-19 patients
- 01/11/21
- Eligo Bioscience enters research, option agreement with GlaxoSmithKline
- 12/21/20
- Ligand, GSK in pact 'leveraging' Icagen's small molecule 'expertise'
- 01/20/21 UBS
- GlaxoSmithKline price target raised to 1,450 GBp from 1,440 GBp at UBS
- 01/20/21
- Fly Intel: Top five analyst downgrades
- 01/20/21 Credit Suisse
- GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
- 01/20/21 Credit Suisse
- GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
- 01/14/21 Morgan Stanley
- 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
- 01/14/21 Oppenheimer
- Essa Pharma price target raised to $20 from $9 at Oppenheimer
- 01/05/21 Argus
- Viatris initiated with a Hold at Argus
- 12/31/20 Ladenburg
- UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
- 01/15/21 B. Riley Securities
- Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
- 12/29/20 Piper Sandler
- Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
- 01/12/21
- Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07
- 10/27/20
- Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B
- 10/27/20
- Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B
- 10/27/20
- Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95
- 10/13/20
- Johnson & Johnson sees 'robutst, double-digit sales growth' in 2021
- 10/13/20
- Johnson & Johnson sees Q4 sales 'around' 2019 levels, consensus $21.52B
- 10/13/20
- Johnson & Johnson raises FY20 adj. EPS view to $7.95-$8.05 from $7.75-$7.95
- 10/13/20
- Johnson & Johnson reports Q3 adj. EPS $2.20, consensus $1.98
- 10/28/20
- GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range
- 10/28/20
- GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago
- 10/08/20
- GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5%
- 07/29/20
- GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER
- 01/21/21
- Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports
- 01/21/21
- Pfizer and BioNTech agree to supply vaccine to WHO co-led effort, Reuters says
- 01/20/21
- Hong Kong set to approve COVID vaccine by Pfizer/BioNTech, SCMP says
- 01/20/21
- Japan inks deal with Pfizer for COVID vaccine for 72M people, Nikkei reports
- 01/13/21
- Johnson & Johnson's one-dose COVID-19 vaccine appears 'promising,' CNBC says
- 01/13/21
- J&J chief science officer sees possible vaccine approval by March, Reuters says
- 01/13/21
- J&J sees U.S. decision on COVID-19 vaccine candidate by March, Bloomberg says
- 01/13/21
- EU lawmaker says J&J likely to submit vaccine approval in Feb., Reuters reports
- 01/12/21
- GSK looks to double blockbusters in portfolio by 2026, Bloomberg says
- 12/31/20
- Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports
- 12/23/20
- Judge rules against White House drug pricing rule, Reuters says
- 12/11/20
- GlaxoSmithKline offered $120 per share for Eidos Therapeutics, Bloomberg says
- 01/12/21
- Fly Intel: Wall Street's top stories for Tuesday
- 01/12/21
- Fly Intel: Wall Street's top stories at midday
- 01/08/21
- Fly Intel: Wall Street's top stories for Friday
- 01/08/21
- Fly Intel: Wall Street's top stories at midday
- 01/14/21
- Fly Intel: Wall Street's top stories for Thursday
- 01/14/21
- Fly Intel: Wall Street's top stories at midday
- 01/13/21
- Fly Intel: Wall Street's top stories for Wednesday
- 12/29/20
- Street Fight: Citi sees opportunity in Arcturus as COVID data prompts downgrades
- 12/31/20
- Fly Intel: Wall Street's top stories for Thursday
- 12/26/20
- Week in review: How Trump's policies moved stocks
- 12/11/20
- Fly Intel: Wall Street's top stories for Friday
- 12/11/20
- Fly Intel: Wall Street's top stories at midday
- 12/15/20
- Notable open interest changes for December 15th
- 12/14/20
- Unusually active option classes on open December 14th
- 12/11/20
- Unusually active option classes on open December 11th
- 12/11/20
- Notable open interest changes for December 11th
- 12/01/20
- Johnson & Johnson call volume above normal and directionally bullish
- 10/13/20
- Unusually active option classes on open October 13th
- 09/23/20
- Unusually active option classes on open September 23rd
- 08/24/20
- Unusually active option classes on open August 24th
- 09/04/20
- GlaxoSmithKline call volume above normal and directionally bullish
- 08/03/20
- Unusually active option classes on open August 3rd
- 07/31/20
- Unusually active option classes on open July 31st
|
|
Earnings
|
Reports Q4 revenue… Reports Q4 revenue $1.33B, consensus $1.24B. Worldwide da Vinci procedures increased approximately 6% compared with Q4 of 2019, reflecting continued disruption caused by the COVID-19 pandemic. The company shipped 326 da Vinci Surgical Systems, a decrease of 3% compared with 336 in Q4 of 2019. The company said, "During 2020, da Vinci procedure volumes and system placements were significantly impacted by the COVID-19 pandemic, as healthcare systems around the world diverted resources to respond to COVID-19. The impact of the COVID-19 pandemic on the Company's business has, and continues to, differ by geography and region. In the U.S., for example, while da Vinci procedures had recovered a significant portion of the pre-COVID-19 levels, the resurgence of COVID-19, particularly later in the fourth quarter and into January, has had, and will likely continue to have, an adverse impact on the Company's procedure volumes. Due to the continued uncertainty around the scope and duration of the pandemic globally, we cannot, at this time, reliably estimate the future impact on our operations and financial results." ShowHide Related Items >><< - 10/27/20
- Intuitive Surgical launches $100M venture capital fund
- 10/15/20
- Intuitive Surgical slides 2.8% to $720 per share after Q3 results
- 10/15/20
- Intuitive Surgical's first 9 months of 2020 saw 'significant impact' from COVID
- 10/15/20
- Intuitive Surgical reports Q3 global da Vinci procedures up 7% from last year
- 12/15/20 Morgan Stanley
- Intuitive Surgical downgraded to Equal Weight on valuation at Morgan Stanley
- 12/15/20 Morgan Stanley
- Intuitive Surgical downgraded to Equal Weight from Overweight at Morgan Stanley
- 11/24/20 Raymond James
- Intuitive Surgical not surprised by J&J robot features, says Raymond James
- 10/16/20 JPMorgan
- Intuitive Surgical price target raised to $785 from $765 at JPMorgan
- 01/21/21
- Notable companies reporting after market close
- 01/13/21
- Intuitive Surgical sees 2020 revenue $4.36B, consensus $4.27B
- 01/13/21
- Intuitive Surgical sees Q4 revenue $1.33B, consensus $1.23B
- 10/15/20
- Intuitive Surgical reports Q3 EPS $2.77, consensus $2.07
- 10/15/20
- Fly Intel: After-Hours Movers
- 07/21/20
- Fly Intel: After-Hours Movers
- 11/12/20
- Early notable gainers among liquid option names on November 12th
- 10/15/20
- Intuitive Surgical options imply 5.8% move in share price post-earnings
|